Tekla Life Sciences Investors
NYSE:HQL · New York Stock Exchange
+$0.11 today
Vol 0.12M · Avg 0.11M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NYSE:HQL · Revenue to Net Income
Key Ratios
Analysis
$79.8M of revenue converted into $186.0M of net income for the selected period. Gross margin is 89.7% and net margin is 712.0%, showing how much revenue survives after costs and taxes. EPS is $6.33, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $86.4M -0.3% | $86.7M +120.1% | $39.4M +23.6% | $31.9M -29.2% | $45.0M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $5.0M -7.2% | $5.4M +2.2% | $5.2M -5.5% | $5.5M -8.7% | $6.1M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $86.4M -0.3% | $86.7M +374.2% | $18.3M -30.5% | $26.3M -32.4% | $38.9M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 100.0% +0.0pp | 100.0% +53.6pp | 46.4% -36.2pp | 82.6% -3.9pp | 86.5% | 9.8% | 28.9% | 38.3% |
| Research & Development | $0 | $0 | $0 +100.0% | -$3 | $0 | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $743.2K -44.2% | $1.3M +47.5% | $903.1K -16.1% | $1.1M +27.6% | $844.0K | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $791.6K -43.0% | $1.4M +18.6% | $1.2M -13.4% | $1.4M +16.8% | $1.2M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $0 -100.0% | $1.9M -93.0% | $27.6M +823.0% | $3.0M -27.8% | $4.1M | $374.2M | $1.2B | $631.8M |
| EBITDA | $85.6M -1.9% | $87.2M +74.6% | $50.0M +149.2% | -$101.6M -248.0% | $68.7M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 99.1% -1.5pp | 100.6% -26.2pp | 126.8% +445.7pp | -318.9% -471.5pp | 152.5% | 5.6% | 46.3% | 42.0% |
| Operating Income | $85.6M +0.3% | $85.3M +1726.5% | -$5.2M +95.0% | -$104.6M -262.1% | $64.5M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 99.1% +0.7pp | 98.4% +111.7pp | -13.3% +315.0pp | -328.3% -471.6pp | 143.3% | 16.6% | 24.1% | 22.0% |
| Interest Income | $349.8K -66.5% | $1.0M +410.2% | $204.4K +308.1% | $50.1K | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $0 -100.0% | $87.2M +216.0% | $27.6M +1141658.2% | $2.4K +130.9% | -$7.8K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $85.6M +0.3% | $85.3M +281.6% | $22.4M +121.4% | -$104.6M -262.1% | $64.5M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 99.1% +0.7pp | 98.4% +41.6pp | 56.8% +385.0pp | -328.3% -471.6pp | 143.3% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | $85.6M +0.3% | $85.3M +281.6% | $22.4M +121.4% | -$104.6M -262.1% | $64.5M | $4.9B | $4.8B | $4.7B |
| Net Margin | 99.1% +0.7pp | 98.4% +41.6pp | 56.8% +385.0pp | -328.3% -471.6pp | 143.3% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $3 -2.6% | $3 +284.8% | $1 +119.4% | -$4 -253.0% | $3 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $3 -2.6% | $3 +284.8% | $1 +119.4% | -$4 -253.0% | $3 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $28.9M +2.9% | $28.1M -0.8% | $28.3M +10.2% | $25.7M +5.9% | $24.3M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $28.9M +2.9% | $28.1M -0.8% | $28.3M +10.2% | $25.7M +5.9% | $24.3M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Gladstone Investment Corporation
NASDAQ:GAIN
$587.92M
Eagle Point Credit Company Inc.
NYSE:ECC
$481.90M
Gladstone Capital Corporation
NASDAQ:GLAD
$421.13M
Crescent Capital BDC, Inc.
NASDAQ:CCAP
$414.33M
Source Capital, Inc.
NYSE:SOR
$375.13M
Barings Corporate Investors
NYSE:MCI
$364.86M
CION Investment Corporation
NYSE:CION
$334.83M
BlackRock TCP Capital Corp.
NASDAQ:TCPC
$286.53M
PennantPark Investment Corporation
NYSE:PNNT
$235.39M
GigCapital7 Corp.
GIG
$172.00M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does HQL generate?
Tekla Life Sciences Investors (HQL) reported $86.39M of revenue in fiscal 2025.
Is HQL profitable?
Tekla Life Sciences Investors (HQL) reported $85.59M of net income, with a net margin of 99.1%.
Explore More
Continue the stock analysis
Jump to another research area for this company.